Management of locally advanced renal cell carcinoma

Cancer Control

Volumn 13, Issue 3, 2006, Pages 199-210

  Rodriguez, Alejandro ^a   Sexton, Wade J ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ALPHA2A INTERFERON; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; BCG VACCINE; CANCER VACCINE; CD3 ANTIBODY; CYTOKINE; FLUOROURACIL; HEAT SHOCK PROTEIN PEPTIDE COMPLEX 96; INTERLEUKIN 2; MONOCLONAL ANTIBODY G250; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; SORAFENIB; SUNITINIB; TUMOR MARKER; UNCLASSIFIED DRUG;

ADVANCED CANCER; ARTERY LIGATION; ARTIFICIAL EMBOLISM; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CELL BASED GENE THERAPY; CLINICAL TRIAL; DRUG ACTIVITY; DRUG EFFICACY; HUMAN; IMMUNE SYSTEM; INFERIOR CAVA VEIN; KIDNEY CARCINOMA; LYMPH NODE METASTASIS; LYMPHADENECTOMY; MICROMETASTASIS; NEPHRECTOMY; PROGNOSIS; RECURRENCE RISK; RENAL ARTERY; REVIEW; STATISTICAL SIGNIFICANCE; SURVIVAL RATE; TUMOR GROWTH; TUMOR THROMBUS; UNSPECIFIED SIDE EFFECT;

EID: 33749128688     PISSN: 10732748     EISSN: 15262359     Source Type: Journal    
DOI: 10.1177/107327480601300307     Document Type: Review

References (114)

1. Zisman A, Pantuck AJ, Wieder J, et al. Risk group assessment and clinical outcome algorithm to predict the natural history of patients with surgically resected renal cell carcinoma. J Clin Oncol. 2002;20:4559-4566.
2. Leibovich BC, Blute ML, Cheville JC, et al. Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma. Cancer. 2003;97:1663-1671.
3. Cheville JC, Blute ML, Zincke H, et al. Stage pT1 conventional (clear cell) renal cell carcinoma: pathological features associated with cancer specific survival. J Urol. 2001;166:453-456.
4. Flanigan RC, Salmon SE, Blumenstein BA, et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med. 2001;345:1655-1659.
5. Mickisch GH, Garin A, van Poppel H, et al. European Organization for Research and Treatment of Cancer (EORTC) Genitourinary Group. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet. 2001;358:966-970.
6. Motzer RJ, Mazumdar M, Bacik J, et al. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol. 1999;17:2530-2540.
7. Jayson M, Sanders H. Increased incidence of serendipitously discovered renal cell carcinoma. Urology.1998;51:203-205.
8. Bosniak MA. The current radiological approach to renal cysts. Radiology. 1986;158:1-10.
9. Dechet CB, Sebo T, Farrow G, et al. Prospective analysis of intraoperative frozen needle biopsy of solid renal masses in adults. J Urol. 1999;162:1282-1284.
10. Dechet CB, Zincke H, Sebo TJ, et al. Prospective analysis of computerized tomography and needle biopsy with permanent sectioning to determine the nature of solid renal masses in adults . J Urol. 2003;169:71-74.
11. Sanchez-Ortiz RF, Madsen LT, Bermejo CE, et al. A renal mass in the setting of a nonrenal malignancy: when is a renal tumor biopsy appropriate? Cancer. 2004;101:2195-2201.
12. Fernandez-Acenero MJ, Galindo M, Bengoechea O, et al. Primary malignant lymphoma of the kidney: case report and literature review. Gen Diagn Pathol. 1998;143:317-320.
13. Motzer RJ, Bacik J, Mariani T, et al. Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear-cell histology. J Clin Oncol. 2002;20:2376-2381.
14. Frank I, Blute ML, Cheville JC, et al. An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based, on tumor stage, size, grade and necrosis: the SSIGN score. J Urol. 2002;168:2395-2400.
15. Fuhrman SA, Lasky LC, Limas C. Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol. 1982;6:655-663.
16. Mian BM, Bhadkamkar N, Slaton JW, et al. Prognostic factors and survival of patients with sarcomatoid renal cell carcinoma. J Urol. 2002;167:65-70.
17. Lam JS, Leppert JT, Figlin RA, et al. Role of molecular markers in the diagnosis and therapy of renal cell carcinoma. Urology. 2005;66(5 suppl):1-9.
18. Harris AL. Hypoxia: a key regulatory factor in tumour growth. Nat Rev Cancer. 2002;2:38-47.
19. Zbar B, Brauch H, Talmadge C, et al. Loss of alleles of loci on the short arm of chromosome 3 in renal cell carcinoma. Nature. 1987;327:721-724.
20. Iliopoulos O, Eng C. Genetic and clinical aspects of familial renal neoplasms. Semin Oncol. 2000;27:138-149.
21. Brauch H, Weirich G, Brieger J, et al. VHL alterations in human clear cell renal cell carcinoma: association with advanced tumor stage and a novel hot spot mutation. Cancer Res. 2000;60:1942-1948.
22. Svastova E, Zilka N, Zat'ovicova M, et al. Carbonic anhydrase IX reduces E-cadherin-mediated adhesion of MDCK cells via interaction with beta-catenin. Exp Cell Res. 2003;290:332-345.
23. Oosterwijk E, Divgi CR, Brouwers A, et al. Monoclonal antibody-based therapy for renal cell carcinoma. Urol Clin North Am. 2003;30:623-631.
24. Grabmaier K, Vissers JL, De Weijert MC, et al. Molecular cloning and immunogenicity of renal cell carcinoma-associated antigen G250. Int J Cancer. 2000;85:865-870.
25. Bui MH, Seligson D, Han KR, et al. Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy. Clin Cancer Res. 2003;9:802-811.
26. Mulders PF, De Mulder PH. The role of adjuvant immunotherapy in renal cell carcinoma. Curr Urol Rep. 2002;3:44-49.
27. Bui MH, Visapaa H, Seligson D, et al. Prognostic value of carbonic anhydrase IX and KI67 as predictors of survival for renal clear cell carcinoma. J Urol. 2004;171(6 pt 1):2461-2466.
28. Yildiz E, Gokce G, Kilicarslan H, et al. Prognostic value of the expression of Ki-67, CD44 and vascular endothelial growth factor, and microvessel invasion, in renal cell carcinoma. BJU Int. 2004;93:1087-1093.
29. Brown DC, Gatter KC. Monoclonal antibody Ki-67: its use in histopathology. Histopathology. 1990;17:489-503.
30. Rioux-Leclercq N, Turlin B, Bansard J, et al. Value of immunohistochemical Ki-67 and p53 determinations as predictive factors of outcome in renal cell carcinoma. Urology. 2000;55:501-505.
31. Visapaa H, Bui M, Huang Y, et al. Correlation of Ki-67 and gelsolin expression to clinical outcome in renal clear cell carcinoma. Urology. 2003;61:845-850.
32. Moch H, Schraml P, Bubendorf L, et al. High-throughput tissue microarray analysis to evaluate genes uncovered by cDNA microarray screening in renal cell carcinoma. Am J Pathol. 1999;154:981-986.
33. Shvarts O, Seligson D, Lam J, et al. p53 is an independent predictor of tumor recurrence and progression after nephrectomy in patients with localized renal cell carcinoma. J Urol. 2005;173:725-728.
34. Paul R, Necknig U, Busch R, et al. Cadherin-6: a new prognostic marker for renal cell carcinoma. J Urol. 2004;171:97-101.
35. Morell-Quadreny L, Rubio J, Lopez-Guerrero JA, et al. Disruption of basement membrane, extracellular matrix metalloproteinases and E-cadherin in renal-cell carcinoma. Anticancer Res. 2003;23:5005-5010.
36. Markovic-Lipkovski J, Brasanac D, Muller GA, et al. Cadherins and integrins in renal cell carcinoma: an immunohistochemical study. Tumori. 2001;87:173-178.
37. Kim HL, Zisman A, Han KR, et al. Prognostic significance of venous thrombus in renal cell carcinoma: are renal vein and inferior vena cava involvement different? J Urol. 2004;171(2 pt 1):588-591.
38. Zisman A, Wieder JA, Pantuck AJ, et al. Renal cell carcinoma with tumor thrombus extension: biology, role of nephrectomy and response to immunotherapy. J Urol. 2003;169:909-916.
39. Rabbani F, Hakimian P, Reuter VE, et al. Renal vein or inferior vena caval extension in patients with renal cortical tumors: impact of tumor histology. J Urol. 2004;171:1057-1061.
40. Naitoh J, Kaplan A, Dorey F, et al. Metastatic renal cell carcinoma with concurrent inferior vena caval invasion: long-term survival after combination therapy with radical nephrectomy, vena caval thrombectomy and post-operative immunotherapy. J Urol.1999;162:46-50.
41. Hatcher PA, Anderson EE, Paulson DF, et al. Surgical management and prognosis of renal cell carcinoma invading the vena cava. J Urol. 1991;145:20-23.
42. Montie JE, El Ammar R, Pontes JE, et al. Renal cell carcinoma with inferior vena cava tumor thrombi. Surg Gynecol Obstet.1991;173:107.
43. Neves RJ, Zincke H. Surgical treatment of renal cancer with vena cava extension. Br J Urol. 1987;59:390-395.
44. Blute ML, Leibovich BC, Lohse CM, et al. The Mayo Clinic experience with surgical management, complications and outcome for patients with renal cell carcinoma and venous tumour thrombus. BJU Int. 2004;94:33-41.
45. Quek ML, Stein JP, Skinner DG. Surgical approaches to venous tumor thrombus. Semin Urol Oncol. 2001;19:88-97.
46. Skinner DG, Pritchett JR, Lieskovsky G, et al. Vena caval involvement by renal cell carcinoma. Surgical resection provides meaningful long-term survival. Ann Surg. 1989;210:387-392.
47. Novick AC, Kaye MC, Cosgrove DM, et al. Experience with cardiopulmonary bypass and deep hypothermia circulatory arrest in the management of retroperitoneal tumors with a large vena caval thrombus. Ann Surg. 1990;212:472-477.
48. Thrasher JB, Paulson DF. Prognostic factors in renal cancer. Urol Clin North Am. 1993;20:247-262.
49. Swierzewski DJ, Swierzewski MJ, Libertino JA. Radical nephrectomy in patients with renal cell carcinoma with venous, vena, caval, and atrial extension. Am J Surg. 1994;168:205-209.
50. Parekh DJ, Cookson MS, Chapman W, et al. Renal cell carcinoma with renal vein and inferior vena caval involvement: clinicopathological features, surgical techniques and outcomes. J Urol. 2005;173:1897-1902.
51. Angermeier KW, Novick AC, Streem SB, et al. Nephron-sparing surgery for renal cell carcinoma with venous involvement. J Urol. 1990;144:1352-1355.
52. Sengupta S, Zincke H, Leibovich BC, et al. Surgical treatment of stage pT3b renal cell carcinoma in solitary kidneys: a case series. BJU Int. 2005;96:54-57.
53. Pritchett TR, Lieskovsky G, Skinner DG. Extension of renal cell carcinoma into the vena cava: clinical review and surgical approach. J Urol. 1986;135:460-464.
54. Langenbuch C. Chirurgie der leber und gallenblase [in German]. Dtsche Chir. 1894;45C:1.
55. Skinner DG, Pfister RF, Colvin R. Extension of renal cell carcinoma into the vena cava: the rationale for aggressive surgical management. J Urol. 1972;107:711-716.
56. Vaislic C, Puel P, Grondin P, et al. Cancer of the kidney invading the vena cava and the heart. Results after 11 years of treatment. J Thorac Cardiovasc Surg. 1986;91:604-609.
57. Marshall FF, Reitz BA, Diamond DA. A new technique for management of renal cell carcinoma involving the right atrium: hypothermia and cardiac arrest. J Urol. 1984;131:103-107.
58. Marshall VF, Middleton RG, Holswade GR, et al. Surgery for renal cell carcinoma in the vena cava. J Urol. 1970;103:414-420.
59. Stewart JR, Carey JA, McDougal WS, et al. Cavoatrial tumor thrombectomy using cardiopulmonary bypass without circulatory arrest. Ann Thorac Surg. 1991;51:717-721.
60. Viljoen JF, Thangathurai D. Anesthetic management in radical surgery for urologic malignancies. In: Skinner DJ, Lieskovsky G, eds. Diagnosis and Management of Genitourinary Cancer. Philadelphia, Pa: WB Saunders Co; 1988:595-600.
61. Treiger BF, Humphrey LS, Peterson CV Jr, et al. Transesophageal echocardiography in renal cell carcinoma: an accurate diagnostic technique for intracaval neoplastic extension. J Urol. 1991;145:1138-1140.
62. Kearney GP, Waters WB, Klein LA, et al. Results of inferior vena cava resection for renal cell carcinoma. J Urol. 1981;125:769-773.
63. Montie JE, el Ammar R, Pontes JE, et al. Renal cell carcinoma with inferior vena cava thrombi. Surg Gynecol Obstet. 1991;173:107-115.
64. Caldarelli G, Minervini A, Guerra M, et al. Prosthetic replacement of the inferior vena cava and the iliofemoral vein for urologically related malignancies. BJU Int. 2002;90:368-374.
65. Marshall FF, Reitz BA. Supradiaphragmatic renal cell carcinoma tumor thrombus: indications for vena caval reconstruction with pericardium. J Urol. 1985;133:266-268.
66. Ciancio G, Soloway M. Resection of the abdominal inferior vena cava for complicated renal cell carcinoma with tumour thrombus. BJU Int. 2005;96:815-818.
67. Robson CJ, Churchill BM, Anderson W. The results of radical nephrectomy for renal cell carcinoma. J Urol. 1969;101:297-301.
68. Blom JH, van Poppel H, Marechal JM, et al. The EORTC Genitourinary Group. Radical nephrectomy with and without lymph node dissection: preliminary results of the EORTC randomized phase III protocol 30881. Eur Urol. 1999;36:570-575.
69. Blute ML, Leibovich BC, Cheville JC, et al. A protocol for performing extended lymph node dissection using primary tumor pathological features for patients treated with radical nephrectomy for clear cell renal cell carcinoma. J Urol. 2004;172:465-469.
70. Studer UE, Scherz S, Scheidegger J, et al. Enlargement of regional lymph nodes in renal cell carcinoma is often not due to metastases. J Urol. 1990;144(2 pt 1):243-245.
71. Minervini A, Lilas L, Morelli G, et al. Regional lymph node dissection in the treatment of renal cell carcinoma: is it useful in patients with no suspected adenopathy before or during surgery? BJU Int. 2001;88:169-172.
72. Vasselli JR, Yang JC, Linehan WM, et al. Lack of retroperitoneal lymphadenectomy predicts survival of patients with metastatic renal cell carcinoma. J Urol. 2001;166:68-72.
73. Johnsen JA, Hellsten S. Lymphatogenous spread of renal cell carcinoma: an autopsy study. J Urol. 1997;157:450-453.
74. Pantuck AJ, Zisman A, Dorey F, et al. Renal cell carcinoma with retroperitoneal lymph nodes: role of lymph node dissection. J Urol. 2003;169:2076-2083.
75. Canfield SE, Kamat AM, Sanchez-Ortiz RF, et al. Renal cell carcinoma with nodal metastases in the absence of distant metastatic disease (clinical stage TxN1-2M0): the impact of aggressive surgical resection on patient outcome. J Urol. 2006;175(3 pt 1):864-869.
76. Ward JF, Blute ML, Cheville JC, et al. The influence of pNx/pN0 grouping in a multivariate setting for outcome modeling in patients with clear cell renal cell carcinoma. J Urol. 2002;168:56-60.
77. deKernion JB, Ramming KP, Smith RB. Natural history of metastatic renal cell carcinoma: a computer analysis. J Urol. 1978;120:148-152.
78. Almgard LE, Fernstrom I, Haverling M, et al. Treatment of renal adenocarcinoma by embolic occlusion of the renal circulation. Br J Urol. 1973;45:474-479.
79. Zielinski H, Szmigielski S, Petrovich Z. Comparison of preoperative embolization followed by radical nephrectomy with radical nephrectomy alone for renal cell carcinoma. Am J Clin Oncol. 2000;23:6-12.
80. Bono AV, Caresano A. The role of embolization in the treatment of kidney carcinoma. Eur Urol. 1983;9:334-337.
81. Mebust WK, Weigel JW, Lee KR, et al. Renal cell carcinoma: angioinfarction. J Urol. 1984;131:231-235.
82. Jennings SB, Austenfeld MS, Basham K. Fatal pulmonary embolus from ischemic necrosis of intra-caval tumor thrombus: a case report. J Urol. 1993;150(5 pt 1):1492-1495.
83. Lammer J, Justich E, Schreyer H, et al. Complications of renal tumor embolization. Cardiovasc Intervent Radiol. 1985;8:31-35.
84. Ciancio G, Vaidya A, Soloway M. Early ligation of the renal artery using the posterior approach: a basic surgical concept reinforced during resection of large hypervascular renal cell carcinoma with or without inferior vena cava thrombus. BJU Int. 2003;92:488-489.
85. Stein M, Kuten A, Halpern J, et al. The value of postoperative irradiation in renal cell cancer. Radiother Oncol. 1992;24:41-44.
86. Gez E, Libes M, Bar-Deroma R, et al. Postoperative irradiation in localized renal cell carcinoma: the Rambam Medical Center experience. Tumori. 2002;88:500-502.
87. Kjaer M, Frederiksen PL, Engelholm SA. Postoperative radiotherapy in stage II and III renal adenocarcinoma: a randomized trial by the Copenhagen Renal Cancer Study Group. Int J Radiat Oncol Biol Phys. 1987;13:665-672.
88. Pizzocaro G, Piva L, Di Fronzo G, et al. Adjuvant medroxyprogesterone acetate to radical nephrectomy in renal cancer: 5-year results of a prospective randomized study. J Urol. 1987;138:1379-1381.
89. Yagoda A, Petrylak D, Thompson S. Cytotoxic chemotherapy for advanced renal cell carcinoma. Urol Clin North Am. 1993;20:303-321.
90. Motzer RJ, Russo P. Systemic therapy for renal cell carcinoma. J Urol. 2000;163:408-417.
91. Chapman AE, Goldstein LJ. Multiple drug resistance: biologic basis and clinical significance in renal-cell carcinoma. Semin Oncol. 1995;22:17-28.
92. Motzer RJ, Berg W, Ginsberg M, et al. Phase II trial of thalidomide for patients with advanced renal cell carcinoma. J Clin Oncol. 2002;20:302-306.
93. Stadler WM, Kuzel T, Shapiro C, et al. Multi-institutional study of the angiogenesis inhibitor TNP-470 in metastatic renal carcinoma. J Clin Oncol. 1999;17:2541-2545.
94. Braybrooke JP, O'Byrne KJ, Propper DJ, et al. A phase II study of razoxane, an antiangiogenic topoisomerase II inhibitor, in renal cell cancer with assessment of potential surrogate markers of angiogenesis. Clin Cancer Res. 2000;6:4697-4704.
95. Lee CP, Patel PM, Selby PJ, et al. Randomized phase II study comparing thalidomide with medroxyprogesterone acetate in patients with metastatic renal cell carcinoma. J Clin Oncol. 2006;24:898-903.
96. Le Francois D, Youn JK, Belehradek J Jr, et al. Evolution of cell-mediated immunity in mice bearing tumors produced by a mammary carcinoma cell line: influence of tumor growth, surgical removal, and treatment with irradiated tumor cells. J Natl Cancer Inst. 1971;46:981-987.
97. Whitney RB, Levy JG, Smith AG. Influence of tumor size and surgical resection on cell-mediated immunity in mice . J Natl Cancer Inst. 1974;53:111-116.
98. Gitlitz BJ, Figlin RA. Cell, gene and vaccine based strategies in kidney cancer. In: Figlin RA, ed. Kidney Cancer: Cancer Treatment and Research. Boston, Mass: Kluwer Academic Publishers; 2003:183-198.
99. Margolin K, Gordon MS, Holmgren E, et al. Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: pharmacologic and long-term safety data. J Clin Oncol. 2001;19:851-856.
100. Bukowski RM. Cytokine combinations: therapeutic use in patients with advanced renal cell carcinoma. Semin Oncol. 2000;27:204-212.
101. Messing EM, Manola J, Wilding G, et al. Eastern Cooperative Oncology Group/Intergroup trial. Phase III study of interferon alfa-NL as adjuvant treatment for resectable renal cell carcinoma: an Eastern Cooperative Oncology Group/Intergroup trial. J Clin Oncol. 2003;21:1214-1222.
102. Pizzocaro G, Piva L, Colavita M, et al. Interferon adjuvant to radical nephrectomy in Robson stages II and III renal cell carcinoma: a multicentric randomized study. J Clin Oncol. 2001;19:425-431.
103. Clark JI, Atkins MB, Urba WJ, et al. Adjuvant high-dose bolus interleukin-2 for patients with high-risk renal cell carcinoma: a cytokine working group randomized trial. J Clin Oncol. 2003;21:3133-3140.
104. Atzpodien J, Schmitt E, Gertenbach P, et al. Adjuvant treatment with interleukin-2 and interferon alpha-2-based chemoimmunotherapy in renal cell carcinoma post tumor nephrectomy: results of a prospectively randomized trial of the German Cooperative Renal Cell Carcinoma Chemoimmunotherapy Group (DGCIN). Br J Cancer. 2005;92:843-846.
105. Sawczuk IS, Graham SD Jr, Miesowicz F, et al. Randomized controlled trial of adjuvant therapy with ex vivo activated T cells (ALT) in T1-3a,b,c or T4N + M renal cell carcinoma. Proc Annu Meet Am Soc Clin Oncol. 1997;16:326a. Abstract.
106. Galligioni E, Quaia M, Merlo A, et al. Adjuvant immunotherapy treatment of renal carcinoma patients with autologous tumor cells and bacillus Calmette-Guérin: five-year results of a prospective randomized study. Cancer. 1996;77:2560-2566.
107. Schwaab T, Tretter CP, Gibson JJ, et al. Immunological effects of granulocyte-macrophage colony-stimulating factor and autologous tumor vaccine in patients with renal cell carcinoma. J Urol. 2004;171:1036-1042.
108. Jocham D, Richter A, Hoffmann L, et al. Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: phase III, randomised controlled trial. Lancet. 2004;363:594-599.
109. Wood CG, Escudier B, Gorelov S, et al. A multicenter randomized study of adjuvant heat-shock protein peptide-complex 96 (HSPPC-96) vaccine in patients with high-risk of recurrence after nephrectomy for renal cell carcinoma (RCC): a preliminary report. J Clin Oncol. 2004;22(suppl):192S.
110. Assikis VJ, Daliani D, Pagliaro L, et al. Phase II study of an autologous tumor derived heat shock protein-peptide complex vaccine (HSPPC-96) for patients with metastatic renal cell carcinoma (mRCC). Proc Annu Meet Am Soc Clin Oncol. 2003;22:386s. Abstract.
111. Hoos A, Levey DL. Vaccination with heat shock protein-peptide complexes: from basic science to clinical applications. Expert Rev Vaccines. 2003;2:369-379.
112. Lam JS, Leppert JT, Belldegrun AS, et al. Adjuvant therapy of renal cell carcinoma: patient selection and therapeutic options. BJU Int. 2005;96:483-488.
113. Motzer RJ, Michaelson MD, Redman BG, et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol. 2006;24:16-24.
114. Ratain MJ, Eisen T, Stadler WM, et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol. 2006;Apr 24, [Epub ahead of print].